Login to Your Account



AAC Wants More Data, Limited Indication for Arcalyst in Gout

By Mari Serebrov
Washington Editor

Wednesday, May 9, 2012
In a bit of a déjà vu, the FDA's Arthritis Advisory Committee (AAC) once again overwhelmingly rejected a sponsor's quest to expand the label of its IL-1 blocker to include the prevention of gout flares.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription